Cubosomes and other potential ocular drug delivery vehicles for macromolecular therapeutics.

INTRODUCTION: Many macromolecular therapeutics designed to treat posterior segment eye diseases (PSEDs) are administered through frequent ocular injection, which can further deteriorate eye health. Due to the high frequency of injection and the high cost of the therapeutics, there is a need to develop new ways in which to deliver these therapeutics: ways which are both safer and more cost effective. AREAS COVERED: Using the most common PSED, age-related macular degeneration, as an example of a debilitating ocular disease, this review examines the key barriers limiting the delivery of macromolecular therapeutics to the posterior segment of the eye and defines the key requirements placed on particulate drug delivery vehicles (DDVs) to be suitable for this application. Recent developments in macromolecular drug delivery to treat this disease as well as the remaining shortcomings in its treatment are surveyed. Lastly, an emerging class of DDVs potentially suited to this application, called cubosomes, is introduced. EXPERT OPINION: Based on their excellent colloidal stability and high internal surface area, cubosomes hold great potential for the sustained release of therapeutics. Novel production methods and a better understanding of the mechanisms through which drug release from these particles can be controlled are two major recent developments toward successful application.

Size and phase control of cubic lyotropic liquid crystal nanoparticles.

The effective use of lyotropic liquid crystalline dispersions, such as cubosomes, as drug delivery vehicles requires that they have tailored physical characteristics that suit specific therapeutics and external conditions. Here, we have developed phytantriol-based cubosomes from a dispersion of unilamellar vesicles and show that we can control their size as well as the critical packing parameter (CPP) of the amphiphilic bilayer through regulation of temperature and salt concentration, respectively. Using the anionic biological lipid 1,2-dipalmi-toylphosphatidylserine (DPPS) to prevent the cubic phase from forming, we show that the addition of phosphate buffered saline (PBS) results in a transition from small unilamellar vesicles to the cubic phase due to charge-shielding of the anionic lipid. Using dynamic light scattering, we show that the cubosomes formed following the addition of PBS are as small as 30 nm; however, we can increase the average size of the cubsosomes to create an almost monodisperse dispersion of cubosomes through cooling. We propose that this phenomenon is brought about through the phase separation of the Pluronic F-127 used to stabilize the cubosomes. To complement previous work using the salt-induced method of cubosome production, we show, using synchrotron small-angle X-ray scattering (SAXS), that we can control the CPP of the amphiphile bilayer which grants us phase and lattice parameter control of the cubosomes.